IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial

Context Glutamine is the main source of energy of the enterocyte and diarrhea and weight loss are frequent in HIV infected patients. Objective To determine the effect of alanyl-glutamine supplementation on intestinal permeability and absorption in these patients. Methods Randomized double-blinde...

Full description

Bibliographic Details
Main Authors: Roberio Dias LEITE, Noelia Leal LIMA, Christiane Araujo Chaves LEITE, Calil Kairalla FARHAT, Richard Littleton GUERRANT, Aldo Angelo Moreira LIMA
Format: Article
Language:English
Published: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE) 2013-03-01
Series:Arquivos de Gastroenterologia
Subjects:
HIV
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032013000100056&lng=en&tlng=en
id doaj-1b9c5f9c96974873aec232d6efef5e99
record_format Article
spelling doaj-1b9c5f9c96974873aec232d6efef5e992020-11-25T02:48:55ZengInstituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)Arquivos de Gastroenterologia1678-42192013-03-01501566310.1590/S0004-28032013000100011S0004-28032013000100056IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trialRoberio Dias LEITENoelia Leal LIMAChristiane Araujo Chaves LEITECalil Kairalla FARHATRichard Littleton GUERRANTAldo Angelo Moreira LIMAContext Glutamine is the main source of energy of the enterocyte and diarrhea and weight loss are frequent in HIV infected patients. Objective To determine the effect of alanyl-glutamine supplementation on intestinal permeability and absorption in these patients. Methods Randomized double-blinded, placebo-controlled study using isonitrogenous doses of alanyl-glutamine (24 g/day) and placebo (glycine, 25 g/day) during 10 days. Before and after this nutritional supplementation lactulose and mannitol urinary excretion were determined by high performance liquid chromatography. Results Forty six patients with HIV/AIDS, 36 of whom were male, with 37.28 ± 3 (mean ± standard error) years were enrolled. Twenty two and 24 subjects were treated with alanyl-glutamine and with glycine respectively. In nine patients among all in the study protocol that reported diarrhea in the 14 days preceding the beginning of the study, mannitol urinary excretion was significantly lower than patients who did not report this symptom [median (range): 10.51 (3.01–19.75) vs. 15.37 (3.93–46.73); P = 0.0281] and lactulose/mannitol ratio was significantly higher [median (range): 0.04 (0.00–2.89) vs. 0.02 (0.00–0.19); P = 0.0317]. There was also a significant increase in mannitol urinary excretion in the group treated with alanyl-glutamine [median (range): 14.38 (8.25–23.98) before vs 21.24 (6.27–32.99) after treatment; n = 14, P = 0.0382]. Conclusion Our results suggest that the integrity and intestinal absorption are more intensely affected in patients with HIV/AIDS who recently have had diarrhea. Additionally, nutritional supplementation with alanyl-glutamine was associated with an improvement in intestinal absorption.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032013000100056&lng=en&tlng=enAbsorcao intestinalGlutaminaHIVPlacebo
collection DOAJ
language English
format Article
sources DOAJ
author Roberio Dias LEITE
Noelia Leal LIMA
Christiane Araujo Chaves LEITE
Calil Kairalla FARHAT
Richard Littleton GUERRANT
Aldo Angelo Moreira LIMA
spellingShingle Roberio Dias LEITE
Noelia Leal LIMA
Christiane Araujo Chaves LEITE
Calil Kairalla FARHAT
Richard Littleton GUERRANT
Aldo Angelo Moreira LIMA
IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial
Arquivos de Gastroenterologia
Absorcao intestinal
Glutamina
HIV
Placebo
author_facet Roberio Dias LEITE
Noelia Leal LIMA
Christiane Araujo Chaves LEITE
Calil Kairalla FARHAT
Richard Littleton GUERRANT
Aldo Angelo Moreira LIMA
author_sort Roberio Dias LEITE
title IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial
title_short IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial
title_full IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial
title_fullStr IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial
title_full_unstemmed IMPROVEMENT OF INTESTINAL PERMEABILITY WITH ALANYL-GLUTAMINE IN HIV PATIENTS: a randomized, double blinded, placebo-controlled clinical trial
title_sort improvement of intestinal permeability with alanyl-glutamine in hiv patients: a randomized, double blinded, placebo-controlled clinical trial
publisher Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE)
series Arquivos de Gastroenterologia
issn 1678-4219
publishDate 2013-03-01
description Context Glutamine is the main source of energy of the enterocyte and diarrhea and weight loss are frequent in HIV infected patients. Objective To determine the effect of alanyl-glutamine supplementation on intestinal permeability and absorption in these patients. Methods Randomized double-blinded, placebo-controlled study using isonitrogenous doses of alanyl-glutamine (24 g/day) and placebo (glycine, 25 g/day) during 10 days. Before and after this nutritional supplementation lactulose and mannitol urinary excretion were determined by high performance liquid chromatography. Results Forty six patients with HIV/AIDS, 36 of whom were male, with 37.28 ± 3 (mean ± standard error) years were enrolled. Twenty two and 24 subjects were treated with alanyl-glutamine and with glycine respectively. In nine patients among all in the study protocol that reported diarrhea in the 14 days preceding the beginning of the study, mannitol urinary excretion was significantly lower than patients who did not report this symptom [median (range): 10.51 (3.01–19.75) vs. 15.37 (3.93–46.73); P = 0.0281] and lactulose/mannitol ratio was significantly higher [median (range): 0.04 (0.00–2.89) vs. 0.02 (0.00–0.19); P = 0.0317]. There was also a significant increase in mannitol urinary excretion in the group treated with alanyl-glutamine [median (range): 14.38 (8.25–23.98) before vs 21.24 (6.27–32.99) after treatment; n = 14, P = 0.0382]. Conclusion Our results suggest that the integrity and intestinal absorption are more intensely affected in patients with HIV/AIDS who recently have had diarrhea. Additionally, nutritional supplementation with alanyl-glutamine was associated with an improvement in intestinal absorption.
topic Absorcao intestinal
Glutamina
HIV
Placebo
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032013000100056&lng=en&tlng=en
work_keys_str_mv AT roberiodiasleite improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial
AT noelialeallima improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial
AT christianearaujochavesleite improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial
AT calilkairallafarhat improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial
AT richardlittletonguerrant improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial
AT aldoangelomoreiralima improvementofintestinalpermeabilitywithalanylglutamineinhivpatientsarandomizeddoubleblindedplacebocontrolledclinicaltrial
_version_ 1724745900738215936